BG
Bellevue Group Portfolio holdings
AUM
$4.54B
1-Year Est. Return
22.5%
1 Year Est. Return
+22.5%
AUM
$4.54B
AUM Growth
+$74.3M
(+1.7%)
Holding
155
Top Buys
| 1 | +$39.2M | |
| 2 | +$38.3M | |
| 3 | +$36.5M | |
| 4 |
Thermo Fisher Scientific
TMO
|
+$20M |
| 5 |
Edgewise Therapeutics
EWTX
|
+$17.7M |
Top Sells
| 1 | +$35.5M | |
| 2 | +$29.9M | |
| 3 | +$25.6M | |
| 4 |
Boston Scientific
BSX
|
+$20M |
| 5 |
Cencora
COR
|
+$19M |
Sector Composition
| 1 | Healthcare | 99.88% |
| 2 | Technology | 0.01% |
| 3 | Consumer Discretionary | 0.01% |
| 4 | Communication Services | 0.01% |
| 5 | Consumer Staples | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
argenx
ARGX
$50.9B
| $315M | 6.94% |
571,039
-7,835
|
|
||
2
Ionis Pharmaceuticals
IONS
$11.6B
| $310M | 6.84% |
7,853,198
|
|
||
3
Neurocrine Biosciences
NBIX
$13.7B
| $229M | 5.04% |
1,820,000
|
|
||
4
Alnylam Pharmaceuticals
ALNY
$63.9B
| $221M | 4.86% |
676,367
-91,780
|
|
||
5
Abbott
ABT
$222B
| $213M | 4.69% |
1,564,022
+7,893
|
|
||
6
Stryker
SYK
$141B
| $212M | 4.67% |
535,089
-31,508
|
|
||
7
Intuitive Surgical
ISRG
$158B
| $206M | 4.54% |
378,728
-47,018
|
|
||
8
Vertex Pharmaceuticals
VRTX
$105B
| $197M | 4.33% |
441,610
+28,539
|
|
||
|
9
Boston Scientific
BSX
$146B
| $190M | 4.18% |
1,765,194
-185,826
|
|
||
10
Revolution Medicines
RVMD
$10.4B
| $168M | 3.71% |
4,579,300
+205,000
|
|
||
11
Agios Pharmaceuticals
AGIO
$2.51B
| $119M | 2.63% |
3,590,150
+75,000
|
|
||
12
Incyte
INCY
$17.2B
| $107M | 2.36% |
1,570,333
-521,447
|
|
||
13
Akero Therapeutics
AKRO
$4.3B
| $106M | 2.33% |
1,985,272
+734,606
|
|
||
14
Scholar Rock
SRRK
$2.78B
| $104M | 2.3% |
2,947,295
+440,405
|
|
||
15
Medtronic
MDT
$122B
| $80.3M | 1.77% |
921,043
-17,312
|
|
||
16
Immunocore
IMCR
$1.68B
| $76.6M | 1.69% |
2,441,830
+1,220,036
|
|
||
17
DexCom
DXCM
$25.9B
| $75.1M | 1.66% |
860,828
-203,280
|
|
||
18
Edwards Lifesciences
EW
$43B
| $69.5M | 1.53% |
889,077
-82,892
|
|
||
19
Insulet
PODD
$22.4B
| $68.8M | 1.52% |
219,013
-52,273
|
|
||
20
Celldex Therapeutics
CLDX
$1.76B
| $67.3M | 1.48% |
3,307,569
+235,954
|
|
||
21
Becton Dickinson
BDX
$53.2B
| $54.6M | 1.2% |
316,732
-27,579
|
|
||
22
Beam Therapeutics
BEAM
$2.64B
| $49.1M | 1.08% |
2,889,288
+493,358
|
|
||
|
23
Thermo Fisher Scientific
TMO
$203B
| $46M | 1.01% |
113,544
+49,312
|
|
||
24
Penumbra
PEN
$9.87B
| $44.7M | 0.98% |
174,050
-30,467
|
|
||
25
UnitedHealth
UNH
$321B
| $44.4M | 0.98% |
142,296
-22,446
|
|